A Clinical study to evaluate the Safety and efficacy of hyaluronic acid injection containing stromal vascular fraction extracted from adipose tissue of patients with enophthalmos

Start Date31 Jan 2025

Sponsor / Collaborator

Bundang CHA Hospital

CTRI/2024/11/077456

/ Not yet recruitingNot ApplicableIIT

Effectiveness of 0.1 percent Hyaluronic Acid with 0.2 percent Chlorhexidine Mouthrinse or 0.2 percent Chlorhexidine Mouthrinse alone as adjunct to scaling and root planing on clinical parameters and salivary aspartate aminotransferase marker in Periodontitis : A Prospective randomized observer blinded study - NIL

Start Date10 Dec 2024

Sponsor / Collaborator

Dr. Reddy's Laboratories Ltd.

IRCT20091012002576N49

/ RecruitingPhase 2/3IIT

Comparisons the effect of hyaluronic acid injection in prevention of adhesions after hysteroscopy septoplasty

Start Date22 Oct 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Hyaluronic acid

100 Translational Medicine associated with Hyaluronic acid

100 Patents (Medical) associated with Hyaluronic acid

3,856

Literatures (Medical) associated with Hyaluronic acid

31 Dec 2025·Future Science OA

Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management

Review

Author: Vaidya, Anuradha ; Ravindran, Selvan ; Dixit, Tanu

This review explores the potential of polymeric nanoparticles (PNPs) as targeted drug delivery systems for arthritic treatment, overcoming the limitations of the present therapy. A thorough literature search was conducted on the databases PubMed, Scopus, and Web of Science to find published articles on the use of polymeric nanoparticles in the treatment of arthritis. This includes synthesis methods, mechanisms in drug delivery, and applications of PNPs. Polymeric nanoparticles showed excellent promise in the management of arthritis through enhanced stability of drugs, controlled and sustained drug release, and reduced systemic side effects. Some of the highlighted biocompatible and targeting capabilities of natural and synthetic polymers include chitosan, hyaluronic acid, and PLGA. Bioactive compounds such as curcumin and resveratrol delivered by PNPs enhanced therapeutic efficacy in preclinical arthritis models. Despite their promise, challenges such as rapid clearance and manufacturing scalability remain critical barriers. Polymeric nanoparticles offer a transformative approach to arthritis management by enabling targeted, sustained, and safe drug delivery. Translation into clinical applications would thus require developments in nanoparticle design, personalized medicine, and scalable production techniques.

01 Dec 2025·Current Pain and Headache Reports

The Current Status and Future Prospects of Intra-articular Injection Therapy for Hip Osteoarthritis: A Review

Review

Author: Wang, Fengxian ; Li, Li ; Song, Xueliang ; Dou, Xiaofan

PURPOSE OF REVIEW:

Hip osteoarthritis constitutes a prevalent condition among individuals aged 55 and above, serving as one of the primary triggers for joint discomfort and impairment, and marking a substantial origin of chronic pain particularly affecting the elderly population. Our article provides an exhaustive summary of the mechanisms of action, therapeutic efficacy, and potential adverse consequences associated with novel therapeutic modalities including glucocorticoids, hyaluronic acid, platelet-rich plasma, mesenchymal stem cells, and stromal vascular fraction. Concurrently, we conducted a comprehensive evaluation of the clinical efficacy and potential applications of various medications.

RECENT FINDINGS:

In comparison to physical therapy, oral analgesics, and other nonsurgical modalities, intra-articular injection therapy is characterized by enhanced safety and greater efficacy. Moreover, when contrasted with surgical intervention, intra-articular injection demonstrates a lower degree of invasiveness and incurs fewer adverse reactions. Intra-articular treatments have shown excellent local efficacy while significantly minimizing adverse reactions in patients. These methods hold significant potential for development but require comprehensive research and thorough discussion within the academic community.

01 Dec 2025·Current Urology Reports

Management of Lower Urinary Tract Symptoms during the Treatment for Non-Muscle Invasive Bladder Cancer

Review

Author: Cheung, Felix ; Ajay, Divya ; Clements, Matthew ; Pietzak, Eugene ; Seiden, Benjamin

PURPOSE OF REVIEW:

This narrative review aims to report upon the existing treatment evidence and strategies for managing lower urinary tract symptoms (LUTS) during treatment, including transurethral resection and intravesical therapy. This review also attempts to examine novel approaches to mitigate treatment-related lower urinary tract symptoms and improve treatment adherence.

RECENT FINDINGS:

There is sparse but promising evidence in improving LUTS secondary to intravesical therapy. Oral agents including phenazopyridine and hyaluronic acid, Bacillus Calmette-Guerin dose reduction, and emerging therapies including beta-3 agonists as well as Onabotulinumtoxin A injections all have demonstrated encouraging improvement in LUTS in limited research. Although recent literature explores new medications and potential strategies for managing intravesical therapy-related LUTS, further research is required to establish efficacy and new consensus on treatment strategies. Further research is also required to establish effective LUTS mitigation strategies with other emerging intravesical therapy regimens.

News (Medical) associated with Hyaluronic acid

01 Aug 2024

·www.prnewswire.com

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 31, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the " Company", Stock Code: 2257.HK, together with its subsidiaries, the " Group" or " Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced a partnership with Gore Range Capital LLC (" Gore Range Capital") (Dallas, TX, USA) for establishment of a joint venture, Sagesse Bio, Inc., to advance its novel RNAi therapeutic products into aesthetic medicine. Sagesse Bio, Inc., a Delaware corporation (" Sagesse Bio"), combines the strength of Sirnaomics' leadership in RNAi-based technology and product development for focal fat reduction and Gore Range Capital's world leading expertise in skin health industry and financial resources, to accelerate clinical development of the company's innovative products for addressing a fast-growing aesthetic medicine market. Sagesse Bio will rapidly advance Sirnaomics lead compound that is IND-enabled and currently in Phase II clinical trials for other indications. Initial indications of interest include body contouring and fat reduction. The founders, board of directors, and newly established executive management team of Sagesse Bio are comprised of a group of well-accomplished senior executives from skin health industry, world-renowned clinicians in dermatology and aesthetic medicine, and leading experts in RNAi medicine. The strategic goal of Sagesse Bio is to become a world-leading aesthetic medicine company with innovative technologies and aesthetic products. Frederick Beddingfield, MD, PhD, serving as Chairperson of the board of directors of Sagesse Bio, is an internationally renowned dermatologist and expert in biopharma and the aesthetics industry, who has led the development of global leading brands such as BOTOX®, JUVEDERM®, LATISSE® and KYBELLA®. He served as Chief Medical Officer of Allergan Medical and Kythera, and as CEO of Sienna Bio and Kira Pharmaceuticals, and currently serves on the board of directors of Cytrellis Biosystems. Dr. Beddingfield stated: "I could not be more excited to help lead and build Sagesse Bio. We have an amazing team with the right experience and a unique opportunity based on the finding of adipocytolysis with good tolerability in human clinical studies, to rapidly advance our IND-approved lead product." Mr. Humberto Antunes, co-founder of Sagesse Bio, partner of Gore Range Capital, former Chairman and CEO of Galderma/Nestlé Skin Health, an internationally renowned executive in skin health industry, comments: "The strategic goal of Sagesse Bio is to deliver innovative and life changing therapies to patients with an initial emphasis on focal fat destruction." "We are thrilled to build this historic partnership: RNAi therapeutic candidate is moving into medical aesthetic product development for body contouring," commented Dr. Patrick Lu, founder, Chairman of the board, executive director, President and CEO of Sirnaomics. "The joint expertise and resources from both Sirnaomics and Gore Range Capital are setting up a strong foundation for a tremendous growth potential of Sagesse Bio with its accelerated product development speed." The board of directors of the Company has approved, and the board of directors and the stockholders of Sagesse Bio have approved, a series of agreements in relation to the partnership (the "Agreements"). The Company and Sagesse Bio have signed the Agreements, which shall become effective only upon being approved by the shareholders of the Company at an upcoming general meeting. Under the partnership arrangement, Sagesse Bio will initiate a clinical evaluation immediately for its leading product candidate, SGY-101, with scientific and technical support from Sirnaomics, receiving assignment and licensing of certain relevant intellectual property rights for the licensed product. In return, Sirnaomics will receive milestone payments of up to US$33 million and a majority equity position of Sagesse Bio with value of approximately US$36 million upon successful equity or debt financing in the future at a minimum pre-financing valuation of Sagesse Bio at US$60 million. Gore Range Capital is responsible for initial funding and building the executive management team and advisory board. In addition, with its well-built domain expertise and extensive networks in the skin health industry, Gore Range Capital is able to provide a hands-on approach for Sagesse Bio's fundraising and business development challenges. About Gore Range Capital Gore Range Capital is focused on investments in the skin health businesses. Gore Range's approach is simple: "We invest in what we know." Over the course of their respective careers the Gore Range team has built domain expertise and extensive networks across multiple areas of healthcare. Through Gore Range Capital, capabilities are channeled to focus on the largest organ and the most visible manifestation of personal identity: the skin. At Gore Range, the hands-on approach of operationally focused private equity is blended with the early-stage guidance needed in venture capital. Formed in 2015, Gore Range works closely with portfolio companies and industry leaders to bring skin health innovations to market. To accomplish this mission, Gore Range leverages its team of experienced healthcare investors, leaders, and practitioners to bring strategic, financial and scientific expertise to its investments. Learn more at: . About Sirnaomics Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAhead™, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Company's GalAhead™ mxRNA technology, is currently in Phase I development. STP237G is the first dual-targeted drug based on a GalAhead™ muRNA technology and is in the late stage of preclinical development. The Company has also had multiple successes with oncology applications through its clinical programs for STP705 and STP707. With the establishment of the it manufacturing facility in China, Sirnaomics is undergoing a transition from a biotech company to a biopharma corporation. Learn more at: . CONTACT: USA Media Contact: George Ji, MBA Head of Finance and Administration Email: [email protected] Asia Media Contact: Johnson Shen, M.A. Senior Business Manager for Investor Relations Email: [email protected] SOURCE Sirnaomics

Phase 1Phase 2

02 Apr 2024

·www.biospace.com

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

BERWYN, Pa.--(BUSINESS WIRE)-- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Boston, MA on April 5-8, 2024. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system. “These are truly exciting times for Nordic Pharma as we near the U.S. launch of LACRIFILL Canalicular Gel, a key milestone in our global expansion strategy,” said Charlotte Phelps, CEO of Nordic Pharma. “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma, Inc., has increased our internal know-how and assets. And with our strong U.S. leadership team and the invaluable support of our Medical Advisory Board, I firmly believe that Nordic Pharma is well-positioned to thrive as a new specialty ophthalmic player and enhance patient care by introducing this novel therapy for dry eye.” “As chairperson of the LACRIFILL U.S. Medical Advisory Board, I am excited about the potential of employing a cross-linked hyaluronic lacrimal filler to optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms,” said Eric D. Donnenfeld, MD. ASCRS attendees are invited to stop by booth #1245 to learn how LACRIFILL Canalicular Gel is changing practice and changing lives. Attendees will also have the opportunity to be among the first Eye Care Professionals to place orders. LACRIFILL Canalicular Gel will be featured at various Refractive and Cornea Day sessions throughout the meeting, including the “LACRIFILL: A Paradigm Shift in Dry Eye Intervention” panel, which will be held on Saturday, April 6th, 2024 and will include the distinguished faculty of Eric Donnenfeld; MD, Preeya Gupta, MD; Darrell White, MD; and Kevin J. Corcoran, COE, CPC, CPMA, FNAO and the Principal of Corcoran & Corcoran. Mark Packer, MD, FACS, CPI, who will be moderating the panel said, “As a lacrimal filler, cross-linked hyaluronic acid provides a new approach to preservation of the tear film, protecting and conforming to delicate tissues while blocking outflow. LACRIFILL Canalicular Gel transforms treatment of the ocular surface, with demonstrated safety and effectiveness for both signs and symptoms of dry eye.” Chief Commercial Officer of Eye Care U.S., Jai Parekh, MD, MBA said, “I am thrilled for Nordic Pharma to be presenting data on LACRIFILL Canalicular Gel at a meeting as important as ASCRS. This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.” For more information and ordering details for LACRIFILL Canalicular Gel visit lacrifill.com. About Nordic Group B.V. Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide. Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies. About Nordic Pharma, Inc. Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace. Safe Harbor This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Disclaimer All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services. View source version on businesswire.com: Contacts Nordic Pharma, Inc. Kate Popova Contracts Administration Lead 610-285-1699 ekaterina.popova@nordicpharma.com Gail Feerrar Director Sales and Marketing 610-285-7152 gail.feerrar@nordicpharma.com Source: Nordic Pharma, Inc. View this news release online at:

Acquisition

14 Mar 2024

·www.prnewswire.com

Empower Aesthetics Highlights Recent Strategic Partnerships: Uplifting Businesses of Medical Aesthetic Industry Entrepreneurs

Private Equity-Backed Platform Pursues New Clinical Partnerships and Sparks Growth of Medical Aesthetics Industry Across the U.S. CHICAGO , March 14, 2024 /PRNewswire/ -- Empower Aesthetics ("Empower" or "the Company"), a national medical aesthetics platform, continues its fast-paced growth while at the same time seeking new clinical partnerships to build out the platform. Empower Aesthetics was formed in July 2023 by Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm focused on microcap investing. Under the leadership of Chief Executive Officer, Alyssa Rapp and Empower's Board of Directors, the Company has solidified four recent partnerships with leading medical aesthetics practices in key U.S. markets: DermaTouch RN Founded in 2006 by Renee Moschitto, Registered Nurse and Founder of the Texas Association of Aesthetic Nurses, DermaTouch RN is a state-of-the-art aesthetic and wellness center that offers minimally invasive medical treatments. Ranked as a top 20 provider of Botox and Juvederm in the country, DermaTouch is consistently recognized as an "Advanced Injector" site and is one of the largest and highest rated providers of Botox, Juvederm and CoolSculpting® ELITE in the Houston area. AWSkin Co. Founded in 2008 in Murfreesboro, Tennessee by Board Certified Nurse Practitioner Amy Hatcher, AWSkin Co. is a medical spa and wellness center offering cosmetic injectables, advanced skincare services, wellness therapies and more. AWSkin Co. has three locations in Cool Springs, Franklin, and Murfreesboro, Tennessee. The Artistry of Face Founded in 2016 by Nurse Practitioner Kelly Heffernan, Artistry of Face offers neurotoxin procedures, dermal filler procedures, body contouring, energy and light-based treatments, as well as a wide range of facial treatments. The practice currently operates out of locations in Albany and Glen Falls, New York. BCRN Aesthetics Founded in 2012 as Rejuviface by Bri and rebranded as BCRN Aesthetics in 2017 by Registered Nurse and Galderma Aesthetic Injector Network (GAIN) Trainer Bri Collins, BCRN Aesthetics is home to Houston's leading advanced aesthetic injectors. The practice's always-evolving knowledge of aesthetics, combined with their unwavering dedication to exceptional customer service and top-tier medical training, makes it one of the most sought-after med spas in the Houston area. "We are committed to building a constellation of clinical partners that are amongst the brightest stars in the space, who deliver and uphold the highest standards of clinical excellence," said Rapp. "The prospect of establishing additional clinical partnerships in the immediate future is a source of great enthusiasm for both me, our executive leadership team and Empower's Board of Directors." Empower Aesthetics is actively pursuing an acquisition strategy, looking for like-minded, growth-oriented entrepreneurs in aesthetics to join a trusted network of clinical leaders, share best practices and deliver superior clinical outcomes. By implementing strategic and operational initiatives intended to elevate the Company's partners, Empower Aesthetics helps clinical leaders grow their businesses, achieve their financial goals, streamline operations and connect with new clients. This private equity-backed support supplies Empower's partners with the resources needed to help grow their businesses, invest in employees, fine-tune operations and see more patients. To learn more about Empower Aesthetics, please visit , or email [email protected]. About Empower Aesthetics Empower Aesthetics is a national aesthetics platform that provides the tools, support and strategy to empower aesthetic owners and practices to reach new heights while maintaining the highest quality of care. With corporate presence in Chicago, Illinois and Austin, Texas, Empower is looking for providers with whom to partner and grow. To learn more about Empower Aesthetics, please visit , or email [email protected]. About Shore Capital Partners Shore Capital, a Chicago-based private equity firm with an office in Nashville, is an investor in microcap companies in the Healthcare, Food and Beverage, Business Services, Industrial, and Real Estate industries. Shore's strategy is to support management partners to grow faster with less risk, through access to capital; world-class board and operational resources; and unmatched networking, development, and shared learnings across the portfolio. From 2020-2023 Shore received recognition from Inc. Magazine as a 4x Top Founder-Friendly Investor and by Pitchbook for being the global leader in private equity total deal volume. Shore targets investments in proven, successful companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately $6 billion of assets under management through various investment vehicles. For more information, please visit . Media Contact: Alec Miszuk | Fishman PR | [email protected] | (630) 484-0797 SOURCE Empower Aesthetics

Executive ChangeAcquisition

100 Deals associated with Hyaluronic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D08043	Hyaluronic acid	-	DB08818

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 2	-	-	01 Jun 2021
Alpha 1-Antitrypsin Deficiency	Phase 1	-	Actelion Pharmaceuticals Ltd.	-
Asthma	Phase 1	-	Actelion Pharmaceuticals Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASTRO2024	Not Applicable	Prostatic Cancer	-	Non-Animal Stabilized Hyaluronic Acid (NASHA) (NASHA rectal spacer)	vsliooacqs(cpukpygmgd) = thtmqpdftz tzuynokppv (fzdmhtqgch ) View more	-	01 Oct 2024
				Non-Animal Stabilized Hyaluronic Acid (NASHA) (No spacer)	vsliooacqs(cpukpygmgd) = ovnjxbxpob tzuynokppv (fzdmhtqgch ) View more
NCT03460158 (CTgov)	Phase 4	-	101	Restylane-L®	ppzypqjrhf(cyfmaqoqwo) = bfbclwgjqo ccnbabbglh (jstadqseaq, bwkqpjptzg - ialbunofbn) View more	-	27 Sep 2024
NCT06178367 (Pubmed)	Phase 3	Asteatosis cutis hyaluronic acid	36	Low Molecular Weight Hyaluronic Acid (LMWHA)	xtyplrvjtj(eyugazwvas) = berdvbxgll ooqrnmsbvo (wfoyykioqy )	Positive	03 Jun 2024
				High Molecular Weight Hyaluronic Acid (HMWHA)	xtyplrvjtj(eyugazwvas) = tsrtpbbshn ooqrnmsbvo (wfoyykioqy )
Abstract P3-07-26 (SABCS2023)	Not Applicable	Breast Cancer ER-positive \| triple-negative	-	FCE-loaded PLGA nanoparticles	kkydawxztq(cdnezumvfd) = pygmtvdzgk dunomghaer (penltummwb ) View more	Positive	01 Mar 2023
EADV2022	Not Applicable	-	-	Cross-linked HA gel 20mg/ml	fxwfpscenq(ksyhndbspl) = 3% wzujscywio (npkfdaqdrm ) View more	-	07 Sep 2022
EADV2022	Not Applicable	Blepharoptosis	20	hyaluronic acid	qiobpxltoh(wxvtnvwrtx) = zobeptfdjm zngoyvccol (ikcpkotroi ) View more	-	07 Sep 2022
				Pneumatic injection of Hyaluronic Acid	qiobpxltoh(wxvtnvwrtx) = uzceqyoglj zngoyvccol (ikcpkotroi ) View more
DDW2022	Not Applicable	Weight Loss	-	CONJUGATED LINOLEIC ACID (CLA), COLLAGEN, AND HYALURONIC ACIDConjugated Linoleic Acid (CLA), COLLAGEN, AND HYALURONIC ACID (Conjugated Linoleic Acid (CLA))	ohyefreuiv(cigowiupil) = xdjzqljqkm gxemwqucbn (ornyhnftom ) View more	-	24 May 2022
IRCT2015081723666N1 (Pubmed \| BMC Womens Health)	Phase 3	Endometrial Carcinoma	50	Hyaluronic acid gel (Ovarian suspension)	qxonaqbauu(zwuycmhgir) = pacncnnmnw ckozjmrpvf (xcptkaxllx ) View more	-	11 Feb 2022
				Hyaluronic acid gel	qxonaqbauu(zwuycmhgir) = hkqtsqdjjj ckozjmrpvf (xcptkaxllx ) View more
EULAR2021	Not Applicable	Osteoarthritis, Knee	160	Low molecular weight (LMW) HA	apeczffgej(toqehsdppx) = improvement was detected by 1 month in 84.3% of cases, and remained until the end of the study in 71.1% of patients lowvclpasr (gsjvtegtuj )	-	02 Jun 2021
				Medium molecular weight (MMW) HA
EULAR2021	Not Applicable	-	100	Subacromial injections of GLA	mjjzgrwxmz(odqfkhobpl) = tiywhlmyev gbivbnsfyj (zmhwjyghmq )	Positive	02 Jun 2021
				Subacromial injections of PRP	mjjzgrwxmz(odqfkhobpl) = ukwwqvsiwl gbivbnsfyj (zmhwjyghmq )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hyaluronic acid

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation